๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fudan University454 Ruijin Hospital276 Shanghai Zhongshan Hospital163 RenJi Hospital135 Children's Hospital of Fudan University84
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shanghai

3827 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
NCT05656053Glioma, Malignant, Computer-Assisted Surgery
Mingge LLC
Observational
30
Shanghai
2021-11-15
Recruiting
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
NCT06021678CD20-positive Non-Hodgkin Lymphoma
Guangzhou Excelmab Inc.
Phase 1/2
415
Zhengzhou, Jinan, Shanghai, Tianjin
2021-11-12
Recruiting
The Impact of Atrial Pressure Change Before and After Combined Procedure
NCT05106270Atrial Fibrillation, Heart Failure
Shanghai 10th People's Hospital
Observational
100
Shanghai
2021-11-10
Recruiting
Top Down Versus Step up in Pediatric Ulcerative Colitis
NCT04999228Ulcerative Colitis, Infliximab, Children
DrugInfliximab
Children's Hospital of Fudan University
Phase 4
40
Shanghai
2021-11-01
Recruiting
Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
NCT05102448Takayasu Arteritis
DrugsTofacitinib·Methotrexate
Shanghai Zhongshan Hospital
Phase 4
76
Shanghai
2021-11-01
Recruiting
Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid Tumors
NCT05098847Liver Metastasis
Fudan University
Phase 2
25
Shanghai
2021-10-29
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
DrugsSavolitinib·Sunitinib·Durvalumab
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
DrugsMosunetuzumab·Lenalidomide·Rituximab
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Active, closed
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
NCT05078931NSCLC
DrugsLenvatinib·Pembrolizumab
Shanghai Chest Hospital
Phase 2
35
Shanghai
2021-10-27
Active, closed
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer
NCT04993430ER-Positive, HER2-Negative Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
46
Shanghai
2021-10-26
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
DrugsPertuzumab·Trastuzumab deruxtecan·Doxorubicin·Trastuzumab
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Active, closed
A Study of FDA018-ADC in Patients With Advanced Solid Tumors
NCT05174637Advanced/ Metastatic Solid Tumors
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
78
Shanghai
2021-10-22
Recruiting
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
NCT04146298Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma, Advanced Cancer
DrugsFludarabine·Cyclophosphamide
Changhai Hospital
Phase 1/2
30
Shanghai
2021-10-21
Active, closed
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
NCT05044897Head and Neck Squamous Cell Carcinoma
DrugSI-B001
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
11
Guilin, Guiyang, Shanghai
2021-10-20
Recruiting
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NCT05331105Neurofibromatosis 1, Plexiform Neurofibromas
Shanghai Kechow Pharma, Inc.
Phase 2
70
Shanghai
2021-10-18
Recruiting
A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
NCT06725524B-cell Non Hodgkin Lymphoma
Shanghai JMT-Bio Inc.
Phase 1
186
Shanghai
2021-10-12
Recruiting
High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia
NCT05072626Biliary Atresia, Infant, Nutrition Support, Medium-chain Triglyceride
Children's Hospital of Fudan University
Observational
300
Shanghai
2021-10-11
Recruiting
Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
NCT04520074Ovarian Cancer
Fudan University
Phase 3
590
Shanghai
2021-10-08
Active, closed
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948Polycythemia Vera
DrugRopeginterferon alfa-2b
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05125055Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
Shanghai Jiao Tong University School of Medicine
Phase 2/3
80
Shanghai
2021-10-01
Recruiting
Renal Artery Fibromuscular Dysplasia Registry
NCT05363748Renal Artery Fibromuscular Dysplasia
Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai
2021-10-01
Active, closed
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807Carcinoma, Non-Small-Cell Lung
DrugsEntrectinib·Crizotinib
Hoffmann-La Roche
Phase 3
217
Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jining, Nanning, Shanghai
2021-09-30
Recruiting
A Study of GC101 TIL in Advanced Melanoma (10hospital)
NCT05098184Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Shanghai
2021-09-26
Recruiting
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
NCT05057052Liver Metastases, Colorectal Cancer Metastatic
Fudan University
Phase 2
25
Shanghai
2021-09-26
Recruiting
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
NCT05098171Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Shanghai
2021-09-26
Recruiting
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT05098197Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects, Effects of Immunotherapy
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Shanghai
2021-09-26
Recruiting
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
NCT05057845Advanced Hepatocellular Carcinoma
DrugsLenvatinib·Tislelizumab
Fudan University
Phase 2
25
Shanghai
2021-09-26
Active, closed
Health Benefits of Air Purifiers in Primary School Students
NCT05016271Cardiopulmonary Function, Child
Fudan University
Not applicable
110
Shanghai
2021-09-22
Recruiting
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
NCT05059379Breast Cancer, Radiotherapy; Complications, Effect of Radiation Therapy
Fudan University
Phase 3
1,650
Shanghai
2021-09-20
Recruiting
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT05018520Diffuse Large B Cell Lymphoma
Ruijin Hospital
Phase 3
640
Shanghai
2021-09-17
Active, closed
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718ALK Fusion-positive Solid or CNS Tumors
DrugAlectinib
Hoffmann-La Roche
Phase 1/2
42
Beijing, Shanghai
2021-09-14
Recruiting
Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus
NCT06196996Brittle Type 1 Diabetes Mellitus
Shanghai Changzheng Hospital
Not applicable
18
Shanghai
2021-09-14
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Beijing, Guangzhou, Zhengzhou, Yichang, Shanghai, Tianjin, Wenzhou
2021-09-13
Active, closed
Clinical Study for Treatment-naรฏve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
NCT04910776Glycogen Storage Disease Type II
DrugAvalglucosidase alfa
Sanofi
Phase 3
17
Qingdao, Shanghai
2021-09-01
Recruiting
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
NCT05069857Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
DrugsApatinib·Camrelizumab
Shanghai Jiao Tong University School of Medicine
Phase 2
46
Shanghai
2021-09-01
Recruiting
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer
NCT05446545Ovarian Cancer
Fudan University
Observational
139
Shanghai
2021-09-01
Recruiting
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
NCT05027828High-grade Serous Ovarian Cancer, Circulating Tumor DNA
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
100
Shanghai
2021-09-01
Active, closed
An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
NCT05764629Chronic Pancreatitis, Diabetes Mellitus
Changhai Hospital
Observational
324
Shanghai
2021-09-01
Active, closed
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
DrugTaletrectinib
Nuvation Bio Inc.
Phase 2
217
Beijing, Zhengzhou, Shanghai, Changsha, Chengdu, Jinan, Wuhan
2021-09-01
Active, closed
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
NCT05043688Resectable Esophageal Squamous Cell Carcinoma
DrugCamrelizumab
Zhigang Li
Phase 3
426
Shanghai, Anyang, Guangzhou, Hefei
2021-09-01
Not yet open
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
NCT04384601Gastric Cancer, Neoadjuvant Chemotherapy
Ruijin Hospital
Phase 3
246
Shanghai
2021-09
Recruiting
Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases
NCT04529629Complicated Adrenal Tumor Diseases
Shanghai Jiao Tong University School of Medicine
Observational
1,000
Shanghai
2021-08-30
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Zhengzhou, Changsha, Nanchang, Changchun, Shanghai, Chengdu, Hangzhou, Beijing
2021-08-27
Recruiting
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
NCT05201430Rectal Cancer
Fudan University
Phase 3
300
Shanghai
2021-08-27
Active, closed
A Study of AK104 Plus Platinum-containing ChemotherapyยฑBevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT04982237Cervical Cancer
Akeso
Phase 3
445
Hangzhou, Hefei, Shanghai
2021-08-27
Recruiting
Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
NCT07776301Breast Cancer
Fudan University
Not applicable
225
Shanghai
2021-08-27
Recruiting
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
NCT05010681Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2
25
Shanghai
2021-08-24
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xiโ€™an
2021-08-17
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
DrugBelzutifan
Merck Sharp & Dohme LLC
Phase 2
355
Beijing, Guangzhou, Shanghai, Chengdu
2021-08-12
Active, closed
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
NCT04923906Non-small Cell Lung Cancer
DrugAumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
624
Shanghai
2021-08-11
By invitation
IT Matters: The Erectile Restoration Registry
NCT04200937Erectile Dysfunction
Boston Scientific Corporation
Observational
450
Beijing, Shanghai
2021-08-05
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
Haerbin, Linyi, Beijing, Shanghai
2021-08-04
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
98
Guangzhou, Wuhan, Beijing, Shanghai
2021-07-28
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
By invitation
The GUARDIAN Trial - Induction Agent Sub-Study
NCT04934683Major Surgery
The University of Texas Health Science Center, Houston
Phase 4
6,254
Shanghai, Beijing, Sichuan
2021-07-25
Recruiting
The GUARDIAN Trial
NCT04884802Blood Pressure
The University of Texas Health Science Center, Houston
Not applicable
6,254
Beijing, Chengdu, Hong Kong, Shanghai, Xuzhou
2021-07-25
By invitation
The GUARDIAN Trial - Vasopressor Sub-Study
NCT04934748Blood Pressure
The University of Texas Health Science Center, Houston
Phase 4
6,254
Beijing, Shanghai, Sichuan
2021-07-25
Active, closed
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
NCT04906993Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
443
Shanghai
2021-07-23
Recruiting
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
NCT04997837Gastric Cancer
DrugsTegafur gimeracil oteracil potassium·Ivonescimab·Oxaliplatin·Capecitabine
Fudan University
Phase 3
433
Shanghai
2021-07-21
Recruiting
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT04954781Intrahepatic Cholangiocarcinoma
DrugTislelizumab
Fudan University
Phase 2
25
Shanghai
2021-07-14
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Recruiting
Enteral Nutrition in Infants With Ileostomy
NCT04707443Nutrition of Ileostomy Infants
Children's Hospital of Fudan University
Observational
110
Shanghai
2021-07-08
By invitation
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China
NCT04989751LGMD, LGMDR2, LGMDR1
Huashan Hospital
Observational
450
Shanghai
2021-07-07
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Recruiting
Baduanjin Training for Depression and Anxiety Patients
NCT05589337Depression Symptoms, Anxiety Symptoms
Shanghai University of Traditional Chinese Medicine
Not applicable
120
Shanghai
2021-07-01
Recruiting
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
NCT04960072Gastrointestinal Tumor
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
50
Shanghai
2021-06-30
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Shanghai
2021-06-29
Active, closed
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994Gastric Cancer
DrugsXelox·Irinotecan
Idience Co., Ltd.
Phase 1/2
87
Beijing, Guangzhou, Shanghai
2021-06-28
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Active, closed
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
NCT04706598Urinary Bladder Neoplasms, Immunotherapy
Fudan University
Phase 1/2
25
Shanghai
2021-06-09
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
DrugsARDT·68Ga-PSMA-11·AAA617
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Establish a Specific Cohort Database for Depressive Disorders
NCT05095662Depressive Disorder
Shanghai Mental Health Center
Observational
80,000
Shanghai
2021-06-01
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
NCT04785196Liposarcoma, Advanced Solid Tumor
DrugsAPG-115·Toripalimab
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Active, closed
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04843098Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Suzhou Junde Biotechnology Co., Ltd
Phase 1/2
108
Shanghai
2021-05-26
Recruiting
Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
NCT04809025Stomach Neoplasms, Endoscopy, Biopsy, Pathology
Fudan University
Observational
510
Shanghai
2021-05-24
Active, closed
Study on the Characteristics of Non-targeted Metabolomics and EEG of Delayed Neurocognitive Recovery in Elderly Patients
NCT05105451Delayed Neurocognitive Recovery
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Observational
80
Shanghai
2021-05-22
Active, closed
Prepectoral and Subpectoral Implant-based Breast Reconstruction
NCT04688697Breast Carcinoma, Breast Reconstruction
Fudan University
Not applicable
300
Shanghai
2021-05-12
Recruiting
Relationship Among Oral Microbiome and NLRP3 Inflammatome and Colorectal Polyps
NCT06724133Search MeSH
Limin Zhang
Observational
80
Shanghai
2021-05-12
Recruiting
A Study of WX390 in Patients With Advanced Solid Tumors
NCT06117540Solid Tumor
DrugWX390
Shanghai Jiatan Pharmatech Co., Ltd
Phase 2
70
Shanghai
2021-05-11
Recruiting
Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System
NCT03206814Hypertension,Essential, Hypertension, Uncontrolled
Istituto Auxologico Italiano
Not applicable
480
Shanghai, Jiangse
2021-05-11
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT04873362Breast Cancer
DrugsTrastuzumab emtansine·Atezolizumab·Trastuzumab
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
DrugAtezolizumab
Hoffmann-La Roche
Phase 3
761
Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2021-05-03
Recruiting
Spinal Cord Stimulation for Parkinsonism
NCT05171205Parkinsonism
Ruijin Hospital
Not applicable
50
Shanghai
2021-05-01
Recruiting
Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study
NCT06708130Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital
Observational
3,000
Shanghai
2021-05-01
Recruiting
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
NCT04903678Retinoblastoma, Extraocular
Eye & ENT Hospital of Fudan University
Not applicable
18
Shanghai
2021-05-01
Active, closed
Phase III Study ๏ผšSHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative
NCT04842617Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage๏ผŒFemale Breast Cancer
DrugDalpiciclib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
5,274
Shanghai
2021-04-30
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
DrugsSorafenib·Atezolizumab·Lenvatinib
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Recruiting
How Early Mobilization Impacts on Diaphragm Thickness in Critically Ill Children
NCT04534296Mechanical Ventilation Complication, Ventilator-induced Diaphragm Dysfunction
Children's Hospital of Fudan University
Not applicable
160
Shanghai
2021-04-26
Recruiting
A Study of GC101 TIL in Advanced Solid Tumors (TR)
NCT04967833Advanced Solid Tumors
DrugTumor Infiltrating Lymphocytes
Shanghai Juncell Therapeutics
Phase EARLY_PHASE1
20
Shanghai
2021-04-22
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
DrugsEnfortumab Vedotin·Gemcitabine·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Active, closed
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
NCT04649489Venous Thrombosis
DrugsAtezolizumab & Bevacizumab·Bevacizumab
Jia Fan
Phase 3
501
Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei
2021-04-19
Active, closed
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
NCT04589650PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
206
Beijing, Shanghai
2021-04-19
Recruiting
Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
NCT04731155Early PCSK9 Inhibitor on Ventricular Remodling
Shanghai Tong Ren Hospital
Phase 4
20
Shanghai
2021-04-12
Recruiting
Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer
NCT04527861Colorectal Cancer, Colon Cancer, Rectal Cancer
Ruijin Hospital
Not applicable
710
Lanzhou, Shenyang, Jinan, Chengdu, Hangzhou, Shanghai
2021-04-08
Recruiting
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
NCT05086614Stage II Colorectal Cancer, Stage III Colorectal Cancer
DrugThymalfasin
Fudan University
Phase 3
2,500
Shanghai
2021-04-01
Active, closed
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT04734262Metastatic Breast Cancer
DrugsNab-paclitaxel·Tislelizumab
Fudan University
Phase 2
98
Shanghai
2021-04-01
Active, closed
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04639180Hepatocellular Carcinoma (HCC)
DrugsRivoceranib·Apatinib·Camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Recruiting
This Study is a Prospective, Multi-center, Real World, Observational Study, Which Aims at Evaluating Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease.
NCT05391815Peripheral Arterial Disease
Shanghai Zhongshan Hospital
Observational
800
Shanghai
2021-04-01
Active, closed
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT04954001Neurofibromatosis 1, Plexiform Neurofibroma, NF1
DrugFCN-159
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2
160
Beijing, Guangzhou, Hangzhou, Shanghai, Shijiazhuang, Wuhan
2021-03-26
Active, closed
PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment
NCT04634058Cholangiocarcinoma, Intrahepatic, PD-L1, CTLA4
DrugIpilimumab N01
Shanghai Zhongshan Hospital
Phase 2
40
Shanghai
2021-03-26
Rows per page Showing 3401–3500 of 3827
Previous 33 34 35 36 37 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai?page=35

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,827 of those studies with a site in Shanghai.

How many clinical trials are recruiting in Shanghai?

2,393 of the 3,827 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 737 have not yet opened recruitment, 588 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.